secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2025-07-07T23:59:59+00:00
Accession:  0001193125-25-155885
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista receives FDA approval for EKTERLY (sebetralstat), first oral on-demand HAE treatment
--------------------------------------------------------------------------------

- FDA approved EKTERLY for acute attacks of hereditary angioedema in patients 12+ years; first oral on-demand therapy.
- Phase 3 KONFIDENT trial (136 patients, 20 countries) showed faster symptom relief vs placebo; published in NEJM.
- KONFIDENT-S open-label extension: median 10 minutes to treat attacks after onset; 1.3 hours to symptom relief for laryngeal/abdominal/breakthrough attacks.
- Launching immediately; prescriptions available today; KalVista Cares patient support program launched.
- CEO Ben Palleiko says EKTERLY has potential to become foundational HAE treatment; conference call at 8:30am ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000119312525155885/0001193125-25-155885-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000119312525155885/d98157d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-155885

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer